Capricor Therapeutics, which received early funding from CureDuchenne, announced regulatory updates for their Deramiocel program to treat Duchenne. The FDA informed Capricor of its intent to hold an Advisory Committee […]
CureDuchenne is pleased that one of the main themes at the recent US FDA Cell and Gene Therapy Roundtable was preserving incentives and leveraging regulatory flexibility and innovation to remove […]
Regenxbio shared positive data from the AFFINITY DUCHENNE trial of RGX-202. In addition to robust microdystrophin expression, Regenxbio reported functional benefits at 9 and 12 months after treatment for all […]
Satellos Biosciences announced their Phase 1b results from their open-label study with SAT-3247, which aims to improve muscle regeneration in Duchenne. SAT-3247 was safe and well-tolerated in 5 individuals with […]
Newport Beach, Calif. and Edmonton, Canada (May 22, 2025) – CureDuchenne Ventures announced an initial $1M investment in Entos Pharmaceuticals Inc (Entos), a biotech company that develops genetic medicines utilizing […]
Newport Beach, Calif., May 21, 2025 — CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, proudly announces the appointment of Brenda Wong, MD, as […]
Event Has Raised Over $6.3 Million to Date, Advancing Lifesaving Research and Therapies for Individuals with Duchenne NEWPORT BEACH, Calif., (May 15, 2025) — CureDuchenne, a leading global nonprofit focused […]
CureDuchenne provided early funding to Entrada Therapeutics. Entrada has received regulatory authorization in Europe to initiate a Phase 1/2 clinical trial of ENTR-601-44 in ambulatory individuals with Duchenne amenable to […]
CureDuchenne was an early funder of Capricor Therapeutics, which has announced completion of a mid-cycle review meeting with the U.S. FDA for their investigational cell therapy, deramiocel, for Duchenne cardiomyopathy. […]
